Evaxion Reports Sustained Three-Year Responses with EVX-01 in Advanced Melanoma

Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress Data supplements unprecedente...

October 20, 2026 | Tuesday | News
Deucrictibant Shows Faster Symptom Relief in Phase 3 HAE Study

Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete sy...

October 12, 2026 | Monday | News
Innovent Reports Phase 3 Success for SYCUME in Inactive Thyroid Eye Disease

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

October 12, 2026 | Monday | News
Aroa Biosurgery Reports Positive Symphony Trial Results in Diabetic Foot Ulcers

Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, announced positive results from a prospective, multicenter randomized controlled tr...

October 06, 2026 | Tuesday | News
AAVantgarde Reports Updated Gene Therapy Data for Usher Syndrome and Stargardt Disease

AAVantgarde Bio (AAVantgarde), the clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases (IRDs) using its propri...

October 06, 2026 | Tuesday | News
Agenus Reports Three-Year Survival Data for BOT+BAL in Recurrent Ovarian Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, announced three-year follow-up results from the ovarian cancer cohort of its 400+ patie...

October 06, 2026 | Tuesday | News
Nanobiotix Reports Positive Phase 1 Data for JNJ-1900 in Recurrent NSCLC

All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injecti...

September 15, 2026 | Tuesday | News
BioMarin Reports Positive Phase 3 VOXZOGO Data in Children with Hypochondroplasia

Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at th...

September 11, 2026 | Friday | News
HUTCHMED Reports Positive Phase III Results for ORPATHYS Plus TAGRISSO in EGFR-Mutated NSCLC

HUTCHMED (China) Limited announces that positive high-level results from the SAFFRON Phase III trial showed ORPATHYS® (savolitinib) plus TAGRISSO®...

August 18, 2026 | Tuesday | News
Otsuka Reports Positive Two-Year Phase 3 VISIONARY Results for VOYXACT in IgA Nephropathy

Phase 3 VISIONARY study met its key secondary endpoint, showing an annualized estimated eGFR slope of +0.3 (95% CI, -0.4 to 0.9) mL/min/1.73 m²/...

August 05, 2026 | Wednesday | News
SciSparc Highlights NeuroThera’s Quantum Analytics Milestone for Clinical Trial Data

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”),  announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a ...

August 04, 2026 | Tuesday | News
Dasher Neuroscience Completes Phase 2 Enrollment for YA-101 in Multiple System Atrophy Trial

Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) dr...

July 31, 2026 | Friday | News
Takeda Reported Phase 3 Zasocitinib Data Showing Strong Skin Clearance in Plaque Psoriasis

Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and pote...

July 30, 2026 | Thursday | News
Ascletis Selected Oral ASC30 and ASC48 Combination for Obesity Clinical Development

ASC48 is a potentially first-in-class oral small molecule GIPR agonist. - ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibit...

July 17, 2026 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close